Characterization of the D8P1C1 Anti-ADAM17 Inhibitory Monoclonal Antibody and Generation of Its Bispecific T-Cell Engager Derivative
International Journal of Molecular Sciences · 24.03.2026 · 27 (7) · 2936
DOI: 10.3390/ijms27072936 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.03.2026. Verfasst von Nayanendu Saha und 5 weiteren Autor:innen. Beteiligte Einrichtung: Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Hauptthemen laut MEDLINE: ADAM17 Protein, Antibodies, Monoclonal, Antibodies, Bispecific, Ovarian Neoplasms. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Experimental Therapeutics Center of Memorial Sloan Kettering, Commonwealth Foundation for Cancer Research.
Abstract (Originalsprache)
EGFR signaling, which requires ligand shedding by ADAM proteases, drives the progression of a variety of cancers, including breast, ovarian and lung. We previously reported the generation and characterization of a fully human, affinity-matured anti-ADAM17 monoclonal antibody, D8P1C1, which inhibits both the proliferation of an array of cancer cell lines in vitro as well as breast cancer growth in a mouse xenograft model. Here, we show that the mAb inhibits the shedding of EGFR ligands and EGFR phosphorylation in cancer cell lines, thus explaining its anti-tumor effects. In a xenograft model with a high-grade serous ovarian cancer (HGSOC) cell line, D8P1C1 showed only modest therapeutic effect, without any discernible toxicity. These results suggest that ovarian cancers are less susceptible than breast cancers to therapeutic targeting of ADAM17- or EGFR-dependent signaling. Radioimmuno PET imaging with 89Zr-DFO-D8P1C1 confirmed tumoral accumulation of the mAb in high-grade and non-high-grade serous ovarian tumor xenografts. Furthermore, we report the generation and preliminary characterization of a bispecific T cell engager derivative of D8P1C1 with improved anti-tumor efficacy in vitro.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Antitumor Assessment Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.
ORCID-Profile: Darren R Veach, Dimitar B Nikolov
Förderung
- NCI NIH HHS
- Experimental Therapeutics Center of Memorial Sloan Kettering
- Commonwealth Foundation for Cancer Research
- Technology Development Investment Fund of Memorial Sloan Kettering
- NIH/NCI Cancer Center
Zitieren
APA
Saha, N., Lee, S. G., de Stanchina, E., Mendoza, R. P., Veach, D. R., & Nikolov, D. B. (2026). Characterization of the D8P1C1 Anti-ADAM17 Inhibitory Monoclonal Antibody and Generation of Its Bispecific T-Cell Engager Derivative. International Journal of Molecular Sciences, 27(7), 2936. https://doi.org/10.3390/ijms27072936
Vancouver
Saha N, Lee SG, de Stanchina E, Mendoza RP, Veach DR, Nikolov DB. Characterization of the D8P1C1 Anti-ADAM17 Inhibitory Monoclonal Antibody and Generation of Its Bispecific T-Cell Engager Derivative. International Journal of Molecular Sciences. 2026;27(7):2936. doi:10.3390/ijms27072936
BibTeX
@article{Saha2026,
author = {Saha, Nayanendu and Lee, Sang Gyu and de Stanchina, Elisa and Mendoza, Rachelle P and Veach, Darren R and Nikolov, Dimitar B},
title = {Characterization of the D8P1C1 Anti-ADAM17 Inhibitory Monoclonal Antibody and Generation of Its Bispecific T-Cell Engager Derivative},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {7},
pages = {2936},
doi = {10.3390/ijms27072936}
}
EUVIMED